Vividion Appoints Patty Allen, Experienced Financial Executive, as Acting Chief Financial Officer
SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that seasoned financial executive Patricia “Patty” Allen has joined Vividion as acting chief financial officer. Ms. Allen is a business finance and operations leader with more than 25 years of experience leading and advising financial and investor relations functions at private and public companies.
“Patty is a highly accomplished industry veteran with deep financial leadership expertise, having led financial functions for both large and small organizations through periods of pivotal growth,” said Jeffrey Hatfield, chief executive officer of Vividion. “As we continue to advance our disruptive platform and take steps towards naming our first small molecule candidates, her leadership will be invaluable to ensuring we have a strong foundation upon which to grow. We are thrilled to welcome her to the Vividion team.”
“Vividion’s distinct approach to applying proprietary insights to address promising, but difficult to reach targets could result in a wide range of small molecule therapeutics that others in the industry have not been able to, to date,” said Ms. Allen. “That scientific know-how and expertise, combined with an exceptionally talented and driven team, positions Vividion to deliver meaningful new treatments that could impact thousands of patients. I’m excited to partner with the team to help build a strong financial organization that will support the company’s continued execution and future success.”
Ms. Allen currently serves on multiple boards of directors for both private and public biotechnology companies. Earlier, she served in financial related roles of increasing responsibility across the biotechnology industry, including at Alnylam, Alkermes and Zafgen. Across those positions, she played an influential role in raising more than $1 billion in both private and public offerings. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. For more information, please visit www.vividion.com.
THRUST Strategic Communications